三生国健（688336）：出海BD迎来突破性进展，临床后期候选药物进展迅速

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [22]. Core Insights - The company reported a revenue of 642 million yuan for the first half of 2025, representing a year-on-year increase of 7.61%. The net profit attributable to shareholders was 190 million yuan, up 46.96%, primarily due to steady sales growth and a decrease in sales expenses compared to the same period last year [1]. - The company has made significant progress in its clinical pipeline, with multiple late-stage candidates advancing rapidly. Notably, the company has achieved a breakthrough in international business development (BD) with Pfizer, securing a record upfront payment of 1.25 billion USD for the exclusive development and commercialization rights of a dual antibody product [6][1]. - The company is actively developing differentiated early-stage pipelines, with innovative targets leading in domestic progress. The first approved IND for BDCA2 monoclonal antibody is currently in Phase I clinical trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) [6]. Financial Summary - The projected total revenue for 2025 is estimated at 4.199 billion yuan, reflecting a year-on-year growth of 251.8%. The net profit attributable to shareholders is expected to reach 2.775 billion yuan, with a growth rate of 293.9% [1][7]. - The earnings per share (EPS) for 2025 is projected to be 4.50 yuan, with a price-to-earnings (P/E) ratio of 12 [1][7]. - The company's total market capitalization is approximately 32.943 billion yuan, with a debt-to-equity ratio of 5.80% [3].